Serum Carbohydrate Antigen 125 Levels in Nonischemic Dilated Cardiomyopathy: A Useful Biomarker for Prognosis and Functional Mitral Regurgitation

Congestive Heart Failure

Volumn 18, Issue 3, 2012, Pages 144-150

  Karaca, Oguz ^a   Guler, Gamze B ^b   Guler, Ekrem ^b   Gunes, H Murat ^b   Alizade, Elnur ^b   Agus, Hicaz Z ^b   Gol, Gokhan ^b   Kahveci, Gokhan ^b   Esen, Ozlem ^c   Esen, A Metin ^b   Turkmen, Muhsin ^b  

^a Bilecik State Hospital   (Turkey)

^b KOSUYOLU HEART AND RESEARCH HOSPITAL   (Turkey)

^c MEMORIAL HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN; CREATININE; HEMOGLOBIN;

ADULT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEALTH STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; NONISCHEMIC DILATED CARDIOMYOPATHY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PULMONARY ARTERY; RECEIVER OPERATING CHARACTERISTIC; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BIOLOGICAL MARKERS; CA-125 ANTIGEN; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84861197013     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00260.x     Document Type: Article

References (23)

1. Wu AH. Management of patients with non-ischemic cardiomyopathy. Heart. 2007;93:403-408.
2. Okutucu S, Oto A. Risk stratification in nonischemic dilated cardiomyopathy: current perspectives. Cardiol J. 2010;17:219-229.
3. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-2159.
4. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer. 1984;50:765-769.
5. Nagele H, Bahlo M, Klapdor R, et al. CA125 and its relation to cardiac function. Am Heart J. 1999;137:1044-1049.
6. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure. Relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities and short term prognosis. J Am Coll Cardiol. 2003;41:1805-1811.
7. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA 125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail. 2005;7:199-203.
8. Topalak O, Saygili U, Soyturk M, et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol. 2002;85:108-113.
9. Kosar F, Aksoy Y, Ozguntekin G, et al. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail. 2006;8:270-274.
10. Vizzardi E, Nodari S, D'Aloia A, et al. CA125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography. 2008;25:955-960.
11. Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B type natriuretic peptide and left atrial volume. Eur J Heart Fail. 2008;10:556-559.
12. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28:230-268.
13. Sjovall K, Nilsson B, Einhorn N. The significance of serum CA125 elevation in malignant and nonmalignant diseases. Gynecol Oncol. 2002;85:175-178.
14. Bergmann JF, Bidart JM, George M, et al. Elevation of CA125 in patients with benign and malignant ascites. Cancer. 1987;59:213-217.
15. Sevinc A, Buyukberger S, Sari R, et al. Elevated serum CA125 in hemodialysis patients with peritoneal, pleural or pericardial fluids. Gynecol Oncol. 2000;77:254-257.
16. Monteiro S, Franco F, Costa S, et al. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol. 2010;140:115-118. Epub 2009 Mar 12.
17. Núñez J, Núñez E, Consuegra L, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart. 2007;93:716-721. Epub 2006 Dec 12.
18. Sikaris KA. CA125-A Test with a Change of Heart. Heart Lung Circ. 2011;20(10):634-640.
19. Ray S. The echocardiographic assessment of functional mitral regurgitation. Eur J Echocardiogr. 2010;11:i11-i17.
20. Lancellotti P, Gérard PL, Piérard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J. 2005;26:1528-1532. Epub 2005 Apr 6.
21. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis. 2002;44:293-321.
22. Steiner J, Guglin M. BNP or NTproBNP? A clinician's perspective Int J Cardiol. 2008;129:5-14. Epub 2008 Apr 18.
23. Faggiano P, D'Aloia A, Brentana L, et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail. 2005;7:57-61.